What is the address of Dr. Karel Christiaens acute geneeskunde?

The registered office of Dr. Karel Christiaens acute geneeskunde is located at Speystraat 2, 9921 Lievegem.

Is Dr. Karel Christiaens acute geneeskunde still active?

Yes. According to the CBE (17 September 2026) Dr. Karel Christiaens acute geneeskunde is active, legal situation “Normale toestand”, started on 29 June 2018.

Is Dr. Karel Christiaens acute geneeskunde registered on Peppol?

Yes, Dr. Karel Christiaens acute geneeskunde is registered on the Peppol network with ID 0208:0698947158.

What is the enterprise number of Dr. Karel Christiaens acute geneeskunde?

The enterprise number of Dr. Karel Christiaens acute geneeskunde is BE0698947158.

When was Dr. Karel Christiaens acute geneeskunde founded?

Dr. Karel Christiaens acute geneeskunde was founded on 29 June 2018.

Who are the directors of Dr. Karel Christiaens acute geneeskunde?

According to the 2025 annual accounts, the directors of Dr. Karel Christiaens acute geneeskunde are: Karel Christiaens.

Is Dr. Karel Christiaens acute geneeskunde a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 June 2018; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Karel Christiaens acute geneeskunde make in 2025?

Dr. Karel Christiaens acute geneeskunde posted a profit after taxes of € 51,094 in financial year 2025.

What is the revenue of Dr. Karel Christiaens acute geneeskunde?

As a small company, Dr. Karel Christiaens acute geneeskunde is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 104,775.

Dr. Karel Christiaens acute geneeskunde (Private Limited)

Dossier Dr. Karel Christiaens acute geneeskunde, printed on 17 September 2026 from databakkes.be/en/0698947158/dr-karel-christiaens-acute-geneeskunde. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Karel Christiaens acute geneeskunde from Lievegem, company number BE0698947158, closed financial year 2025 with a result of € 51,094 after tax. For that financial year Dr. Karel Christiaens acute geneeskunde recorded a gross margin of € 104,775 and equity of € 146,405. Compared with financial year 2024, the result moved from € 44,238 to € 51,094. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.

What it is worth Growing

€ 146,405

▲ 30% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 51,094

▲ 15% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 40,712

▲ 82% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 17,166 paid out

34 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 68,246

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 197,588

▲ 7% vs 2024

€ 22,649 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 3,496

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 7,295

▲ 169% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -8,233 Gross margin 2022: € -8,233 First fiscal year in the series	€ 68,700 Gross margin 2023: € 68,700 ▲ € 76,933 vs 2022 (€ -8,233) Favourable step	€ 84,413 Gross margin 2024: € 84,413 ▲ 23% vs 2023 (€ 68,700) Favourable step	€ 104,775 Gross margin 2025: € 104,775 ▲ 24% vs 2024 (€ 84,413) Favourable step	▲ 24%
Profit after taxes	€ -7,962 Profit after taxes 2022: € -7,962 First fiscal year in the series	€ 47,448 Profit after taxes 2023: € 47,448 ▲ € 55,410 vs 2022 (€ -7,962) Favourable step	€ 44,238 Profit after taxes 2024: € 44,238 ▼ 7% vs 2023 (€ 47,448) Unfavourable step	€ 51,094 Profit after taxes 2025: € 51,094 ▲ 15% vs 2024 (€ 44,238) Favourable step	▲ 15%
Equity	€ 40,731 Equity 2022: € 40,731 First fiscal year in the series	€ 88,179 Equity 2023: € 88,179 ▲ 116% vs 2022 (€ 40,731) Favourable step	€ 112,477 Equity 2024: € 112,477 ▲ 28% vs 2023 (€ 88,179) Favourable step	€ 146,405 Equity 2025: € 146,405 ▲ 30% vs 2024 (€ 112,477) Favourable step	▲ 30%
Total debts	€ 15,235 Total debts 2022: € 15,235 First fiscal year in the series	€ 36,108 Total debts 2023: € 36,108 ▲ 137% vs 2022 (€ 15,235) Unfavourable step	€ 218,118 Total debts 2024: € 218,118 ▲ € 182,011 vs 2023 (€ 36,108) Unfavourable step	€ 241,311 Total debts 2025: € 241,311 ▲ 11% vs 2024 (€ 218,118) Unfavourable step	▲ 11%
Cash	€ 4,963 Cash 2022: € 4,963 First fiscal year in the series	€ 74,287 Cash 2023: € 74,287 ▲ € 69,324 vs 2022 (€ 4,963) Favourable step	€ 22,427 Cash 2024: € 22,427 ▼ 70% vs 2023 (€ 74,287) Unfavourable step	€ 40,712 Cash 2025: € 40,712 ▲ 82% vs 2024 (€ 22,427) Favourable step	▲ 82%
Land & buildings	-	-	€ 257,375 Land & buildings 2024: € 257,375 First fiscal year in the series	€ 242,553 Land & buildings 2025: € 242,553 ▼ 6% vs 2024 (€ 257,375) Unchanged	▼ 6%
Retained profit	€ 28,331 Retained profit 2022: € 28,331 First fiscal year in the series	€ 75,779 Retained profit 2023: € 75,779 ▲ 167% vs 2022 (€ 28,331) Favourable step	€ 100,077 Retained profit 2024: € 100,077 ▲ 32% vs 2023 (€ 75,779) Favourable step	€ 134,005 Retained profit 2025: € 134,005 ▲ 34% vs 2024 (€ 100,077) Favourable step	▲ 34%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 19,940 Dividend 2024: € 19,940 Unchanged (€ 0) Unchanged	€ 17,166 Dividend 2025: € 17,166 ▼ 14% vs 2024 (€ 19,940) Unchanged	▼ 14%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 185,352 Bank debt 2024: € 185,352 Unchanged (€ 0) Unfavourable step	€ 197,588 Bank debt 2025: € 197,588 ▲ 7% vs 2024 (€ 185,352) Unfavourable step	▲ 7%
Balance sheet total	€ 55,966 Balance sheet total 2022: € 55,966 First fiscal year in the series	€ 124,287 Balance sheet total 2023: € 124,287 ▲ 122% vs 2022 (€ 55,966) Unchanged	€ 330,595 Balance sheet total 2024: € 330,595 ▲ 166% vs 2023 (€ 124,287) Unchanged	€ 387,715 Balance sheet total 2025: € 387,715 ▲ 17% vs 2024 (€ 330,595) Unchanged	▲ 17%

Key figures of Dr. Karel Christiaens acute geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Karel Christiaens acute geneeskunde?

What happened at Dr. Karel Christiaens acute geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 24, 2026 New annual accounts for financial year 2025: profit of € 51,094 (▲ 15% vs 2024). filed late Source: NBB ↗
Jun 29, 2018 Start of the company according to the CBE. KBO

In short

From € 7,962 loss in 2022 to € 51,094 profit in 2025.

Paid € 69,464 in corporate taxes since 2022.

Best year ever: 2025, with € 51,094 profit.

Paid out € 37,106 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Karel Christiaens acute geneeskunde? We notify you, reason included.

Follow Dr. Karel Christiaens acute geneeskunde

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Karel Christiaens

Dr. Karel Christiaens acute geneeskunde

Behind Dr. Karel Christiaens acute geneeskunde is Karel Christiaens.

See the full network in the app

Directors

According to the 2025 annual accounts

Karel Christiaens

Bestuurder

Establishments

Establishment units

Physical locations of this company

Registered office

Speystraat 2

9921 Lievegem

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0698.947.158
VAT number: BE 0698.947.158
Registered office: Speystraat 2, 9921 Lievegem
Names & denominations: Dr. Karel Christiaens acute geneeskunde
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 29 June 2018
Peppol: Active · Active since 17 Dec 2025

View on CBE Public ↗ Annual accounts (NBB) ↗